Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemiaDeepa Bhojwani, Susan R. Rheingold, Constance M. Yuan et al.|Leukemia|2018Cited by 209
A phase 1 study of the CXCR4 antagonist plerixafor in combination with high‐dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators’ Consortium study (POE 10‐03)Todd M. Cooper, Patrick A. Brown, Edward Allan R. Sison et al.|Pediatric Blood & Cancer|2017Cited by 73